OBJECTIVE: To compare mortality risks among type 2 diabetes (T2D) patients being treated with glibenclamide, gliclazide, or glimepiride. METHODS: Retrospective observational cohort studies of primary care-based diabetes register were carried out. Risk of total and cardiovascular (CVD) mortality was evaluated in cohort of T2D patients that were treated with either glibenclamide (n=50,341), glimepiride (n=2479) or gliclazide (n=11,368). Cox regression was used for multifactor evaluation. A cross-sectional evaluation of oral anti-diabetic drug (OAD) structure for 2005 and 2007 was also performed, as well as age at the time of death was compared in the timeframe between 2002 and 2007. RESULTS: Total mortality was lower for gliclazide and glimepiride, vs. glibenclamide cohort: HRs 0.33 (95% CI 0.26-0.41), p<0.001 and 0.605 (95% CI 0.413-0.886), p<0.01 respectively. CVD mortality risk reduction vs. glibenclamide was significant only in gliclazide cohort: 0.29 (95% CI 0.21-0.38), p<0.001. Glibenclamide prescriptions had changed from 64.0% (95% CI 63.5-64.5) to 59.5% (95% CI 9.7-10.4). Age at the time of death for OAD-treated patients increased by 6.27 (95% CI 3.67-8.87)yrs, p<0.001. CONCLUSION: Glibenclamide treatment of T2D is associated with greater risk of all-cause mortality, vs. gliclazide or glimepiride treatment, and CVD mortality, vs. gliclazide treatment.
OBJECTIVE: To compare mortality risks among type 2 diabetes (T2D) patients being treated with glibenclamide, gliclazide, or glimepiride. METHODS: Retrospective observational cohort studies of primary care-based diabetes register were carried out. Risk of total and cardiovascular (CVD) mortality was evaluated in cohort of T2D patients that were treated with either glibenclamide (n=50,341), glimepiride (n=2479) or gliclazide (n=11,368). Cox regression was used for multifactor evaluation. A cross-sectional evaluation of oral anti-diabetic drug (OAD) structure for 2005 and 2007 was also performed, as well as age at the time of death was compared in the timeframe between 2002 and 2007. RESULTS: Total mortality was lower for gliclazide and glimepiride, vs. glibenclamide cohort: HRs 0.33 (95% CI 0.26-0.41), p<0.001 and 0.605 (95% CI 0.413-0.886), p<0.01 respectively. CVD mortality risk reduction vs. glibenclamide was significant only in gliclazide cohort: 0.29 (95% CI 0.21-0.38), p<0.001. Glibenclamide prescriptions had changed from 64.0% (95% CI 63.5-64.5) to 59.5% (95% CI 9.7-10.4). Age at the time of death for OAD-treated patients increased by 6.27 (95% CI 3.67-8.87)yrs, p<0.001. CONCLUSION:Glibenclamide treatment of T2D is associated with greater risk of all-cause mortality, vs. gliclazide or glimepiride treatment, and CVD mortality, vs. gliclazide treatment.
Authors: Elisabetta Patorno; Elizabeth M Garry; Amanda R Patrick; Sebastian Schneeweiss; Victoria G Gillet; Olesya Zorina; Dorothee B Bartels; John D Seeger Journal: Drug Saf Date: 2015-03 Impact factor: 5.606
Authors: Elisabetta Patorno; Amanda R Patrick; Elizabeth M Garry; Sebastian Schneeweiss; Victoria G Gillet; Dorothee B Bartels; Elvira Masso-Gonzalez; John D Seeger Journal: Diabetologia Date: 2014-09-12 Impact factor: 10.122
Authors: Kevin M Pantalone; Michael W Kattan; Changhong Yu; Brian J Wells; Susana Arrigain; Anil Jain; Ashish Atreja; Robert S Zimmerman Journal: Diabetes Care Date: 2010-03-09 Impact factor: 19.112
Authors: Ulrik M Mogensen; Charlotte Andersson; Emil L Fosbøl; Tina K Schramm; Allan Vaag; Nikolai M Scheller; Christian Torp-Pedersen; Gunnar Gislason; Lars Køber Journal: Diabetologia Date: 2014-09-10 Impact factor: 10.122
Authors: S Ioacara; C Guja; O Georgescu; S Martin; A Sirbu; M Purcaru; S Fica Journal: Acta Endocrinol (Buchar) Date: 2017 Jul-Sep Impact factor: 0.877
Authors: Gijs W D Landman; Geertruide H de Bock; Kornelis J J van Hateren; Peter R van Dijk; Klaas H Groenier; Rijk O B Gans; Sebastiaan T Houweling; Henk J G Bilo; Nanne Kleefstra Journal: PLoS One Date: 2014-02-12 Impact factor: 3.240